Vetoquinol : Résultat 2023 conforme – Pas d’indication pour 2024 – A priori pas d’annonce M&A immédiate à anticiper
>ROC avant GW en ligne, à 16,3% du CA - Vétoquinol publie un EBITDA à 113 M€ (-4,3%), un ROC contributif à 85 M€ (-13,7%) et un RN de 55,6 M€ (+15,7% / css : 55 M€e).A fin 2023, la situation de cash net atteint 130 M€ contre 76 M€ fin 2022.Un dividende de 0,85 € (vs 0,8 € en 2022) sera proposé. Pas de guidance.Pas d’indication sur la tendance T1, ni de guidance : peu de raison de modifier nos estimations - 1/ Le ROC se situe dans la fourchet...V?toquinol is a global player in the animal health sector, serving both the livestock (cattle and pigs) and pet (dogs and cats) markets. Co. designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region, as an independent entity. Co. is also active in the therapeutic fields of anti-infectives, pain-inflammation and cardiology-nephrology treatment. As of Dec 31 2013, Co.'s product portfolio included brands such as Aurizon®, Epiphen®, Ipakitine®, Marbocyl®, Propalin®, Tolf?dine®, Tolfine®, Clavaseptin®, and Vetprofen®. Co.'s brands are V?toquinol, Tomlyn, and Evsco in the U.S.A. and Equistro for the horse range.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.